These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11496467)

  • 41. Congress has its brain on drug benefits.
    Birnbaum JH
    Fortune; 2003 Jan; 147(1):178. PubMed ID: 12602124
    [No Abstract]   [Full Text] [Related]  

  • 42. Sword or shield? An overview and competitive analysis of the marketing of "authorized generics".
    Zain S
    Food Drug Law J; 2007; 62(4):739-77. PubMed ID: 18557229
    [No Abstract]   [Full Text] [Related]  

  • 43. Long way down--pharmaceutical companies fear falling off 'patent cliff'.
    Sklan A
    Pharm Pat Anal; 2012 Jul; 1(3):240. PubMed ID: 24386667
    [No Abstract]   [Full Text] [Related]  

  • 44. Economic aspects of the new Spanish laws on pharmaceutical preparations.
    Antoñanzas F; Oliva J; Pinillos M; Juàrez C
    Eur J Health Econ; 2007 Sep; 8(3):297-300. PubMed ID: 17401592
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmaceuticals issue brief: pharmaceutical assistance programs: year end report--2004.
    Seay M
    Issue Brief Health Policy Track Serv; 2004 Dec; ():1-26. PubMed ID: 15724309
    [No Abstract]   [Full Text] [Related]  

  • 46. The subsidy of pharmaceuticals in Australia: processes and challenges.
    Sansom L
    Aust Health Rev; 2004 Nov; 28(2):194-205. PubMed ID: 15527399
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Does generic entry lower the prices paid for pharmaceuticals in Australia? A comparison before and after the introduction of the mandatory price-reduction policy.
    Spinks J; Chen G; Donovan L
    Aust Health Rev; 2013 Nov; 37(5):675-81. PubMed ID: 24160374
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Angst about exclusivity: The potential cost of incentivizing makers of generic drugs.
    Chakradhar S; Khamsi R
    Nat Med; 2017 Oct; 23(10):1114-1116. PubMed ID: 28985215
    [No Abstract]   [Full Text] [Related]  

  • 49. Perspectives. Will we try to manage care again? This time, for drugs?
    Clemmitt M
    Med Health; 2000 Jun; 54(25):suppl 1-4. PubMed ID: 11009923
    [No Abstract]   [Full Text] [Related]  

  • 50. Generic drug firm settles claim that it was paid to stay out of market.
    Dyer O
    BMJ; 2015 Apr; 350():h2282. PubMed ID: 25920419
    [No Abstract]   [Full Text] [Related]  

  • 51. Can price and regulatory controls replace free market competition in the drug industry?
    Buc NL; Levitt GM
    Healthspan; 1993 Nov; 10(10):30-2. PubMed ID: 10130839
    [No Abstract]   [Full Text] [Related]  

  • 52. [Medication supply of privately insured patients in 2010].
    Wild F
    Versicherungsmedizin; 2012 Jun; 64(2):85-6. PubMed ID: 22808648
    [No Abstract]   [Full Text] [Related]  

  • 53. Affordable prescription drugs--state and federal action.
    Ohio Nurses Rev; 2003 Aug; 78(7):4. PubMed ID: 15134064
    [No Abstract]   [Full Text] [Related]  

  • 54. The effect of generic competition on the price of brand-name drugs.
    Lexchin J
    Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Basing prescription drug payment on economic analysis: the case of Australia.
    Drummond MF
    Health Aff (Millwood); 1992; 11(4):191-6. PubMed ID: 1483639
    [No Abstract]   [Full Text] [Related]  

  • 56. Protect pharmaceutical innovation.
    Musselwhite LW; Andrews J
    Science; 2010 Jun; 328(5984):1354; author reply 1354-5. PubMed ID: 20538934
    [No Abstract]   [Full Text] [Related]  

  • 57. Eliminating innovation: how price controls limit access.
    Ingram J
    J Leg Med; 2011 Jan; 32(1):115-28. PubMed ID: 21391059
    [No Abstract]   [Full Text] [Related]  

  • 58. Provider boycotts--a review of the Merck-Medco decision. Merck-Medco Managed Care L.L.C. v. Rite Aid Corporation.
    Becker S
    Health Care Law Mon; 2000 May; ():10-8. PubMed ID: 14743588
    [No Abstract]   [Full Text] [Related]  

  • 59. Pharmaceuticals and medical devices: business practices.
    Steiner DJ
    Issue Brief Health Policy Track Serv; 2013 Dec; ():1-36. PubMed ID: 24482889
    [No Abstract]   [Full Text] [Related]  

  • 60. [Pfizer: TLV decision about antilipemic agents is founded on wrong basis].
    Brun J; Ohlsson-Onerud A; Sörensen N
    Lakartidningen; 2009 Apr 22-28; 106(17):1193-4; discussion 1194. PubMed ID: 19530431
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.